Cargando…

The Choice Between Advanced Therapies for Parkinson’s Disease Patients: Why, What, and When?

When oral dopaminergic medication falls short in the treatment of Parkinson’s disease, patients are left with motor response fluctuations and dyskinesias that may have a large impact on functioning in daily life. They may benefit from one of the currently available advanced treatments, namely deep b...

Descripción completa

Detalles Bibliográficos
Autores principales: Dijk, Joke M., Espay, Alberto J., Katzenschlager, Regina, de Bie, Rob M.A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: IOS Press 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7592668/
https://www.ncbi.nlm.nih.gov/pubmed/32651333
http://dx.doi.org/10.3233/JPD-202104
_version_ 1783601232431022080
author Dijk, Joke M.
Espay, Alberto J.
Katzenschlager, Regina
de Bie, Rob M.A.
author_facet Dijk, Joke M.
Espay, Alberto J.
Katzenschlager, Regina
de Bie, Rob M.A.
author_sort Dijk, Joke M.
collection PubMed
description When oral dopaminergic medication falls short in the treatment of Parkinson’s disease, patients are left with motor response fluctuations and dyskinesias that may have a large impact on functioning in daily life. They may benefit from one of the currently available advanced treatments, namely deep brain stimulation, continuous levodopa-carbidopa intestinal gel, and continuous subcutaneous apomorphine infusion. The indication, choice between the separate advanced treatments and the timing can be challenging and will be discussed against the background of the progressive nature of the disease, the heterogeneity of disease manifestation and variable patient characteristics.
format Online
Article
Text
id pubmed-7592668
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher IOS Press
record_format MEDLINE/PubMed
spelling pubmed-75926682020-10-30 The Choice Between Advanced Therapies for Parkinson’s Disease Patients: Why, What, and When? Dijk, Joke M. Espay, Alberto J. Katzenschlager, Regina de Bie, Rob M.A. J Parkinsons Dis Review When oral dopaminergic medication falls short in the treatment of Parkinson’s disease, patients are left with motor response fluctuations and dyskinesias that may have a large impact on functioning in daily life. They may benefit from one of the currently available advanced treatments, namely deep brain stimulation, continuous levodopa-carbidopa intestinal gel, and continuous subcutaneous apomorphine infusion. The indication, choice between the separate advanced treatments and the timing can be challenging and will be discussed against the background of the progressive nature of the disease, the heterogeneity of disease manifestation and variable patient characteristics. IOS Press 2020-09-01 /pmc/articles/PMC7592668/ /pubmed/32651333 http://dx.doi.org/10.3233/JPD-202104 Text en © 2020 – IOS Press and the authors. All rights reserved https://creativecommons.org/licenses/by-nc/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution Non-Commercial (CC BY-NC 4.0) License (https://creativecommons.org/licenses/by-nc/4.0/) , which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review
Dijk, Joke M.
Espay, Alberto J.
Katzenschlager, Regina
de Bie, Rob M.A.
The Choice Between Advanced Therapies for Parkinson’s Disease Patients: Why, What, and When?
title The Choice Between Advanced Therapies for Parkinson’s Disease Patients: Why, What, and When?
title_full The Choice Between Advanced Therapies for Parkinson’s Disease Patients: Why, What, and When?
title_fullStr The Choice Between Advanced Therapies for Parkinson’s Disease Patients: Why, What, and When?
title_full_unstemmed The Choice Between Advanced Therapies for Parkinson’s Disease Patients: Why, What, and When?
title_short The Choice Between Advanced Therapies for Parkinson’s Disease Patients: Why, What, and When?
title_sort choice between advanced therapies for parkinson’s disease patients: why, what, and when?
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7592668/
https://www.ncbi.nlm.nih.gov/pubmed/32651333
http://dx.doi.org/10.3233/JPD-202104
work_keys_str_mv AT dijkjokem thechoicebetweenadvancedtherapiesforparkinsonsdiseasepatientswhywhatandwhen
AT espayalbertoj thechoicebetweenadvancedtherapiesforparkinsonsdiseasepatientswhywhatandwhen
AT katzenschlagerregina thechoicebetweenadvancedtherapiesforparkinsonsdiseasepatientswhywhatandwhen
AT debierobma thechoicebetweenadvancedtherapiesforparkinsonsdiseasepatientswhywhatandwhen
AT dijkjokem choicebetweenadvancedtherapiesforparkinsonsdiseasepatientswhywhatandwhen
AT espayalbertoj choicebetweenadvancedtherapiesforparkinsonsdiseasepatientswhywhatandwhen
AT katzenschlagerregina choicebetweenadvancedtherapiesforparkinsonsdiseasepatientswhywhatandwhen
AT debierobma choicebetweenadvancedtherapiesforparkinsonsdiseasepatientswhywhatandwhen